About Castration-Resistant Prostate Cancer (CRPC) Treatment Prostate cancer is also known as carcinoma of the prostate is cancer of the prostate gland that affects only the male population. It is a slow progressive disease. CRPC is an inveterate stage of prostate cancer, in which almost 90% of individuals develop metastases, specifically in the skeleton. The major therapies involved in the treatment of CRPC are hormonal therapy and chemotherapy. Technavio’s analysts forecast the global castration-resistant prostate cancer treatment market to grow at a CAGR of 9.01% during the period 2017-2021. Covered in this report The report covers the present scenario and the growth prospects of the global castration resistant prostate cancer treatment market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs. The market is divided into the following segments based on geography: • Americas • APAC • EMEA Technavio's report, Global Castration-Resistant Prostate Cancer (CRPC) Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and... Research Beam Model: Research Beam Product ID: 1696913 3500 USD New
Global castration resistant prostate cancer treatment market 2017-2021
 
 

Global castration resistant prostate cancer treatment market 2017-2021

  • Category : Healthcare
  • Published On : July   2017
  • Pages : 87
  • Publisher : Technavio
 
 
 
About Castration-Resistant Prostate Cancer (CRPC) Treatment

Prostate cancer is also known as carcinoma of the prostate is cancer of the prostate gland that affects only the male population. It is a slow progressive disease. CRPC is an inveterate stage of prostate cancer, in which almost 90% of individuals develop metastases, specifically in the skeleton. The major therapies involved in the treatment of CRPC are hormonal therapy and chemotherapy.

Technavio’s analysts forecast the global castration-resistant prostate cancer treatment market to grow at a CAGR of 9.01% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global castration resistant prostate cancer treatment market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio's report, Global Castration-Resistant Prostate Cancer (CRPC) Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Astellas Pharma
• Johnson & Johnson
• Sanofi
• Valeant

Other prominent vendors
• Active Biotech
• Advaxis
• ANI Pharmaceuticals
• Athenex
• Bavarian Nordic
• Bayer
• Bristol-Myers Squibb
• CureVac
• GlaxoSmithKline
• Innocrin Pharmaceutical
• Merck
• Myovant Sciences
• Northwest Biotherapeutics
• OncoGenex Pharmaceuticals
• Oncolytics Biotech
• Orion
• Sotio
• Madrigal Pharmaceuticals)
• Takeda Pharmaceutical
• Teva Pharmaceutical Industries

Market driver
• Physician’s preference toward hormonal therapy
• For a full, detailed list, view our report

Market challenge
• High cost of treatment
• For a full, detailed list, view our report

Market trend
• Increasing consolidation in cancer treatment market
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.




PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Market outline
• CRPC
PART 05: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 06: Pipeline landscape
PART 07: Market segmentation by therapy
• Hormonal therapy
• Chemotherapy
• Others
PART 08: Geographical segmentation
• CRPC treatment market in Americas
• CRPC treatment market in EMEA
• CRPC market in APAC
PART 09: Decision framework
PART 10: Drivers and challenges
• Market drivers
• Market challenges
PART 11: Market trends
• Increasing consolidation in cancer treatment market
• Emergence of targeted therapies and immunotherapies
PART 12: Vendor landscape
• Competitive landscape
PART 13: Key vendor analysis
• Astellas Pharma
• Johnson & Johnson
• Sanofi
• Valeant
• Other prominent vendors
PART 14: Appendix
• List of abbreviations

PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 
REQUEST SAMPLE    ASK FOR DISCOUNT